Evidence map›Paper›PMID 34595453›Full record

ArticleClinical hematology international2020

Sorafenib Induced Complete Cytogenetic and Molecular Response in a Chronic Eosinophilic Leukemia Case with t(12;13) Translocation.

Federica Ricci, Serena Balducci, Francesca Guerrini, Susanna Grassi, Elena Ciabatti, Claudia Baratè, Maria Immacolata Ferreri, Cecilia Giuliani, Angelo Valetto, Mario Petrini and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical hematology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Federica RicciDepartment of Clinical and Experimental Medicine, UO Hematology, University of Pisa, Pisa, Italy.
Serena BalducciDepartment of Clinical and Experimental Medicine, UO Hematology, University of Pisa, Pisa, Italy.
Francesca GuerriniDepartment of Clinical and Experimental Medicine, UO Hematology, University of Pisa, Pisa, Italy.
Susanna GrassiDepartment of Clinical and Experimental Medicine, UO Hematology, University of Pisa, Pisa, Italy.
Elena CiabattiDepartment of Clinical and Experimental Medicine, UO Hematology, University of Pisa, Pisa, Italy.
Claudia BaratèUO Hematology, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Maria Immacolata FerreriUO Cytogenetics, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Cecilia GiulianiUO Cytogenetics, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Angelo ValettoUO Cytogenetics, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Mario PetriniDepartment of Clinical and Experimental Medicine, UO Hematology, University of Pisa, Pisa, Italy.
Sara GalimbertiDepartment of Clinical and Experimental Medicine, UO Hematology, University of Pisa, Pisa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Chronic eosinophilic leukemiaETV6/FLT3Sorafenibt(12;13)

Identifiers

PMID34595453
PMCPMC8432331

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.